Urban-Kowalczyk Małgorzata, Śmigielski Janusz, Strzelecki Dominik
Department of Affective and Psychotic Disorders, Healthy Aging Research Centre (HARC), Medical University of Lodz, Lodz, Poland.
Department of Geriatrics, Healthy Aging Research Centre (HARC), Medical University of Lodz, Lodz, Poland.
Neuropsychiatr Dis Treat. 2016 Apr 15;12:863-8. doi: 10.2147/NDT.S101647. eCollection 2016.
Links between endorphins and dopaminergic transmission have not been fully explored in schizophrenia. Both endorphins excess and deficiency were postulated. CGRP is probably involved in dopaminergic transmission. The aim of this study was the evaluation of beta-endorphin (BE) and CGRP blood concentrations before and after treatment of severe schizophrenia.
Seventy patients treated with various antipsychotics, with severe symptoms of schizophrenia (51 with positive symptoms, 19 with negative symptoms), 15 first-degree relatives, and 44 healthy controls were included in the study. BE and CGRP blood concentrations were measured during patients severe schizophrenia and in their stable mental state after treatment. The results were compared with relatives and controls.
BE and CGRP concentrations in patients with negative symptoms were higher than in relatives and in controls. BE levels in patients with positive symptoms were lower than in patients with negative symptoms (P<0.0000) and controls (P<0.0006). No significant changes in CGRP concentration were found in patient samples. CGRP levels in these samples were independent of treatment, but they were significantly higher than in relatives and controls. After the treatment, BE level decreased in patients with negative symptoms (P<0.0001) and increased in patients with positive symptoms (P<0.0000). No differences in BE concentration between patients in stable mental state, their relatives, and controls were found.
Effective antipsychotic treatment results in "normalization" of BE level. Specific changes in BE concentration could be involved in dopaminergic transmission and related to some symptoms of schizophrenia.
内啡肽与多巴胺能传递之间的联系在精神分裂症中尚未得到充分研究。曾假定内啡肽存在过量和不足两种情况。降钙素基因相关肽(CGRP)可能参与多巴胺能传递。本研究的目的是评估重度精神分裂症患者治疗前后β-内啡肽(BE)和CGRP的血浓度。
本研究纳入了70例使用各种抗精神病药物治疗、有重度精神分裂症症状的患者(51例有阳性症状,19例有阴性症状)、15名一级亲属和44名健康对照者。在患者处于重度精神分裂症状态时及其治疗后精神状态稳定时测量BE和CGRP的血浓度。将结果与亲属和对照者进行比较。
有阴性症状的患者中BE和CGRP浓度高于亲属和对照者。有阳性症状的患者中BE水平低于有阴性症状的患者(P<0.0000)和对照者(P<0.0006)。在患者样本中未发现CGRP浓度有显著变化。这些样本中的CGRP水平与治疗无关,但显著高于亲属和对照者。治疗后,有阴性症状的患者BE水平下降(P<0.0001),有阳性症状的患者BE水平上升(P<0.0000)。处于精神状态稳定的患者与其亲属和对照者之间的BE浓度无差异。
有效的抗精神病药物治疗可使BE水平“正常化”。BE浓度的特定变化可能参与多巴胺能传递,并与精神分裂症的某些症状相关。